Welcome back to my semi-regular column tracking the ups and downs in small-cap biotech. Here, I take a look at Bellus Health (BLU) and OncoSec Medical (ONCS). (Read to the end for quick hits on Northwest Biotherapeutics (NWBO) and Ampio Pharmaceuticals (AMPE).)
As a reminder, I’m taking requests for companies to cover, so reach out to me on Twitter (DMs are open), email, or in the comment section of the column.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
GOSS has great potential
I’m a 93 y/o with no credit card to join. May I have free access ?